These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 31685262)

  • 21. DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis.
    Mai V; Tanguay VF; Guay CA; Bertoletti L; Magnan S; Turgeon AF; Lacasse Y; Lega JC; Provencher S
    J Thromb Thrombolysis; 2020 Oct; 50(3):661-667. PubMed ID: 32052314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
    Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR;
    Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Direct Oral Anticoagulants for Acute Treatment of Venous Thromboembolism in Older Adults: A Network Meta-Analysis of Randomised Controlled Trials.
    Pessôa RL; Kessler VG; Becker GG; Garcia GM; Duarte Araldi PV; Aver PV
    Vasc Endovascular Surg; 2024 Aug; 58(6):633-639. PubMed ID: 38706248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer.
    Wang Y; Wang M; Ni Y; Liang Z
    Hematology; 2020 Dec; 25(1):63-70. PubMed ID: 31984870
    [No Abstract]   [Full Text] [Related]  

  • 26. Early Time Courses of Recurrent Venous Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer.
    Cohen AT; Creeper KJ; Alikhan R; Er C; Connors JM; Huisman MV; Munoz A; Vescovo G; Bauersachs R; Ageno W; Agnelli G; Becattini C
    Thromb Haemost; 2024 Jul; 124(7):676-683. PubMed ID: 38196077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Net Clinical Benefit of Direct Oral Anticoagulants in Patients With Cancer and Venous Thromboembolism: A Systematic Review and Trade-Off Analysis.
    Yan YD; Ding Z; Pan MM; Xia Q; Cui JJ; Wang LW; Zhang C; Gu ZC
    Front Cardiovasc Med; 2020; 7():586020. PubMed ID: 33304929
    [No Abstract]   [Full Text] [Related]  

  • 28. Factor Xa Inhibition for the Treatment of Venous Thromboembolism Associated With Cancer: A Meta-Analysis of the Randomised Controlled Trials.
    Murphy AC; Koshy AN; Farouque O; Yeo B; Raman J; Kearney L; Yudi MB
    Heart Lung Circ; 2022 May; 31(5):716-725. PubMed ID: 34896013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Modern anticoagulation with factor Xa inhibitors in oncology: is the gastrointestinal bleeding rate (also) decisive?].
    Raithel M; Haibach M; Kremenevski I; Arnold E; Ringwald J
    Z Gastroenterol; 2023 Apr; 61(4):411-419. PubMed ID: 35878607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.
    Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE
    Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of cancer-associated venous thromboembolism].
    Di Nisio M
    G Ital Cardiol (Rome); 2018 Sep; 19(9 Suppl 1):7S-12S. PubMed ID: 30284557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct oral anticoagulants for cancer-associated venous thromboembolisms: a systematic review and network meta-analysis.
    Samaranayake CB; Anderson J; McCabe C; Zahir SF; W Upham J; Keir G
    Intern Med J; 2022 Feb; 52(2):272-281. PubMed ID: 32896977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers.
    Lee JH; Lee JH; Jo KW; Huh JW; Oh YM; Lee JS
    J Gynecol Oncol; 2020 Jan; 31(1):e10. PubMed ID: 31789000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G; Zhang R; Wu X; Wang D; Ying K
    Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis.
    Vedovati MC; Germini F; Agnelli G; Becattini C
    Chest; 2015 Feb; 147(2):475-483. PubMed ID: 25211264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison between direct factor Xa inhibitors and low-molecular-weight heparin for efficacy and safety in the treatment of cancer-associated venous thromboembolism: A meta-analysis.
    Yang M; Li J; Sun R; Wang Y; Xu H; Yang B; Wu X; Yu L
    J Cancer Res Ther; 2019; 15(7):1541-1546. PubMed ID: 31939435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct Oral Anticoagulants in Patients With Active Cancer: A Systematic Review and Meta-Analysis.
    Sabatino J; De Rosa S; Polimeni A; Sorrentino S; Indolfi C
    JACC CardioOncol; 2020 Sep; 2(3):428-440. PubMed ID: 34396250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
    Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.